Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
BMC Cardiovasc Disord. 2020 Mar 11;20(1):128. doi: 10.1186/s12872-020-01411-6.
Hypertension is a major contributing factor to cardiovascular disease and is a leading cause of death in the world. The association between hepatic enzymes and hypertension has been reported in limited studies and the findings are inconsistent; data from Bangladeshi adults are not available yet. This study was conducted to estimate the prevalence of elevated liver enzymes and evaluate the association of elevated liver enzymes with hypertension in Bangladeshi adults.
In this cross-sectional study, 302 blood samples were collected from adult participants and analyzed the serum concentrations of alanine and aspartate aminotransferase (ALT, AST), alkaline phosphatase (ALP), and γ-glutamyltransferase (GGT) and other markers related to hypertension. Hypertension was defined as resting SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg. Associations between elevated liver enzymes and hypertension were evaluated by multinomial logistic regression.
The mean concentrations of serum ALT, AST and GGT were significantly higher in the hypertensive group compared to the normotensive group (p < 0.01, p < 0.01 and p < 0.001, respectively). Overall, 49.2% of subjects in the hypertensive group and 38.1% of individuals in the normotensive group had at least one or more elevated liver enzymes. The prevalence of elevated ALT, AST, and GGT was significantly higher among participants in the hypertensive group compared to the normotensive group (p < 0.01, p < 0.01 and p < 0.001, respectively). An increasing trend for elevated liver enzymes was observed with increasing blood pressure. Serum ALT and GGT showed an independent relationship with hypertension.
The prevalence of elevated liver enzymes was higher in hypertensive individuals. Increased serum ALT and GGT activities were positively associated with hypertension in Bangladeshi adults.
高血压是心血管疾病的主要致病因素,也是全球范围内的主要致死原因。已有研究报道了肝酶与高血压之间的相关性,但研究结果并不一致;目前尚无孟加拉成年人的数据。本研究旨在评估孟加拉成年人中肝酶升高的流行情况,并探讨肝酶升高与高血压之间的关系。
本横断面研究共采集了 302 份成年参与者的血液样本,分析了血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)和 γ-谷氨酰转移酶(GGT)等肝酶以及与高血压相关的其他标志物的浓度。高血压定义为静息收缩压(SBP)≥140mmHg 和/或舒张压(DBP)≥90mmHg。采用多项逻辑回归评估肝酶升高与高血压之间的关系。
与血压正常组相比,高血压组的血清 ALT、AST 和 GGT 浓度显著升高(p<0.01、p<0.01 和 p<0.001)。总体而言,高血压组 49.2%的患者和血压正常组 38.1%的患者至少有一种或多种肝酶升高。高血压组 ALT、AST 和 GGT 升高的患病率明显高于血压正常组(p<0.01、p<0.01 和 p<0.001)。随着血压的升高,肝酶升高的患病率呈上升趋势。血清 ALT 和 GGT 与高血压呈独立相关。
高血压患者肝酶升高的患病率较高。血清 ALT 和 GGT 活性升高与孟加拉成年人的高血压呈正相关。